安必平收盘上涨1.43%，滚动市盈率1213.14倍，总市值27.14亿元

Group 1 - The core viewpoint of the article highlights the financial performance and market position of Anbiping, a company in the medical device industry, which has a significantly high PE ratio compared to its peers [1][2] - As of July 8, Anbiping's closing price was 29.01 yuan, with a PE ratio of 1213.14, and a total market capitalization of 2.714 billion yuan [1] - The average PE ratio for the medical device industry is 51.58, with a median of 37.46, placing Anbiping at the 122nd position among its industry peers [1][2] Group 2 - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - In the latest quarterly report for Q1 2025, the company reported revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49% [1] - The gross profit margin for Anbiping stands at 61.97% [1]